Download PDF

1. Company Snapshot

1.a. Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.


It also has a research collaboration agreement with Pfizer Inc.and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc.The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on BEAM

Beam Therapeutics' recent performance was negatively impacted by a wider-than-expected loss of $1.09 per share in Q4, despite topping revenue estimates. The company incurred a narrower-than-expected loss, but the magnitude of the loss overshadowed the positive news. Furthermore, the lack of significant updates on pipeline development and the absence of any new product approvals or launches in the recent earnings release contributed to the negative sentiment. The company's cash runway is expected to support operating plans into 2027, but this does not offset the current negative sentiment.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal

Dec -04

Source: seekingalpha.com

Card image cap

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Nov -27

Source: zacks.com

Card image cap

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov -12

Source: globenewswire.com

Card image cap

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

Nov -04

Source: zacks.com

Card image cap

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov -04

Source: globenewswire.com

Card image cap

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Nov -03

Source: globenewswire.com

Card image cap

Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Oct -29

Source: zacks.com

Card image cap

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Oct -22

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.43%)

6. Segments

Genetic Medicines

Expected Growth: 14.43%

Beam Therapeutics Inc.'s Genetic Medicines segment growth of 14.43% is driven by increasing adoption of gene editing technologies, rising prevalence of genetic disorders, and advancements in CRISPR-Cas9 gene editing. Additionally, strategic partnerships, expanding pipeline, and growing investments in research and development are contributing to the segment's rapid growth.

7. Detailed Products

Base Editing

A precise and efficient gene editing technology that enables the direct, irreversible conversion of one DNA base to another without making a double-stranded break in the genome.

Prime Editing

A highly efficient and precise gene editing technology that combines the precision of CRISPR-Cas9 with the efficiency of homology-directed repair.

Adeno-Associated Virus (AAV) Vectors

A viral vector technology used to deliver therapeutic genes to cells, enabling the treatment of genetic diseases.

CRISPR-Cas9 Gene Editing

A precise and efficient gene editing technology that enables the editing of genes by targeting specific sequences of DNA.

8. Beam Therapeutics Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Beam Therapeutics Inc. has a moderate threat of substitutes due to the presence of alternative gene editing technologies such as CRISPR and zinc finger nucleases. However, the company's proprietary base editing technology provides a unique value proposition that differentiates it from competitors.

Bargaining Power Of Customers

Beam Therapeutics Inc. has a low bargaining power of customers due to the lack of alternative treatment options for genetic diseases. This gives the company significant pricing power and negotiating leverage with customers.

Bargaining Power Of Suppliers

Beam Therapeutics Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment. However, the company's reliance on a few key suppliers for critical components may limit its negotiating power.

Threat Of New Entrants

Beam Therapeutics Inc. faces a high threat of new entrants due to the growing interest in gene editing technologies and the potential for new companies to enter the market. The company's proprietary technology and intellectual property provide some barriers to entry, but new entrants may still pose a significant threat.

Intensity Of Rivalry

Beam Therapeutics Inc. operates in a highly competitive industry with multiple companies developing gene editing technologies. The company faces intense rivalry from established players and new entrants, which may lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 15.00%
Debt Cost 13.34%
Equity Weight 85.00%
Equity Cost 13.34%
WACC 13.34%
Leverage 17.65%

11. Quality Control: Beam Therapeutics Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Stoke Therapeutics

A-Score: 4.4/10

Value: 1.3

Growth: 5.2

Quality: 8.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
IGM Biosciences

A-Score: 3.8/10

Value: 9.4

Growth: 7.1

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Editas Medicine

A-Score: 3.3/10

Value: 6.2

Growth: 3.9

Quality: 3.6

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Agenus

A-Score: 3.2/10

Value: 9.4

Growth: 2.1

Quality: 4.6

Yield: 0.0

Momentum: 2.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Beam Therapeutics

A-Score: 3.2/10

Value: 6.6

Growth: 3.2

Quality: 3.7

Yield: 0.0

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
AIM ImmunoTech

A-Score: 3.1/10

Value: 8.0

Growth: 4.3

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

27.09$

Current Price

27.09$

Potential

-0.00%

Expected Cash-Flows